Skip to main content
J

JINGHUA PHARMACEUTICAL GROUP CO., LTD. — Investor Relations & Filings

Ticker · 002349 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,680 across all filing types
Latest filing 2026-04-22 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 002349

About JINGHUA PHARMACEUTICAL GROUP CO., LTD.

https://www.ntjhzy.com

Jinghua Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company’s portfolio encompasses traditional Chinese medicines (TCM), chemical active pharmaceutical ingredients (APIs), and finished chemical preparations. Key products include renowned traditional formulations such as Wangshi Baochi Wan and Ji Desheng Sheyao, alongside essential APIs like Phenobarbital and Primidone. The group operates multiple manufacturing bases equipped with advanced production lines and maintains rigorous quality control standards. By integrating traditional medicinal heritage with modern pharmaceutical technology, the company serves both domestic and international healthcare markets, focusing on therapeutic areas such as digestive health, emergency medicine, and neurological treatments.

Recent filings

Filing Released Lang Actions
关于调整公司2025年限制性股票激励计划相关事项的公告
Remuneration Information Classification · 1% confidence The document is an official announcement by the company’s board regarding adjustments to its 2025 restricted stock incentive (equity compensation) plan, including details on decision procedures, price adjustments due to dividends, committee and legal opinions. It is not a full financial report or dividend notice, nor is it a simple regulatory update; it directly concerns executive/share incentive remuneration. This matches the Remuneration Information category (DEF 14A).
2026-04-22 Chinese
2025年度非经营性资金占用及其他关联方占用资金往来情况的专项报告
Audit Report / Information Classification · 1% confidence The document is a special audit report (专项报告) issued by an external accounting firm (BDO China Shu Lun Pan) on non-operating fund occupation and related-party fund transactions for the 2025 financial year. It includes audit procedures, reconciliations with audited financial statements, signed by certified public accountants, and is not a full annual report or simple announcement. This matches the definition of a standalone audit report (AR).
2026-04-22 Chinese
2025年度独立董事述职报告（王煦）
Governance Information Classification · 1% confidence The document is an annual performance report (“述职报告”) by an independent director detailing governance activities, committee attendance, independence adherence, and oversight actions. It is not a financial report (10-K/IR), not an earnings release or management discussion of results, nor a notice of dividend or proxy materials. It falls squarely within corporate governance disclosures about board structure, director duties, and compliance with governance rules. Therefore it is a Governance Information filing (CGR).
2026-04-22 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 1% confidence The document is a standalone internal control self-assessment report (“内部控制自我评价报告”) covering detailed evaluation of internal controls, scope, procedures, conclusions, and defect remediation for the year ending December 31, 2025. It is not an Annual Report or mere announcement but a full internal control audit. Under the defined categories, this aligns most closely with “Audit Report / Information” (Code: AR), which covers standalone audit and internal control evaluation reports.
2026-04-22 Chinese
公司章程（2026年4月）
Governance Information Classification · 1% confidence The document is the full text of ‘‘章程’’ (the Articles of Association or corporate charter) of 精华制药集团股份有限公司, detailing the company’s internal rules, governance structure, shareholders’ meetings, board of directors, management responsibilities, share capital provisions, and related corporate governance procedures. This is not an AGM presentation, financial report, or regulatory announcement but a governance document setting out the company’s bylaws. Therefore it fits the Governance Information category.
2026-04-22 Chinese
董事会薪酬与考核委员会核查意见
Remuneration Information Classification · 1% confidence The document is the Remuneration and Appraisal Committee’s verification opinions of the Board of Directors, detailing resolutions on the remuneration management measures, annual salary assessment, and adjustments to the restricted stock incentive plan for directors and senior management. This is a compensation report for top executives and directors, matching the “Remuneration Information (DEF 14A)” category.
2026-04-22 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.